PRPO

Precipio, Inc. (PRPO) - 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Precipio, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: A healthcare biotechnology company operating two complementary divisions: a Pathology Services Division providing specialized cancer diagnostic testing (primarily hematologic malignancies) and a Products Division developing proprietary diagnostic assays (HemeScreen and IV-Cell). The company utilizes an integrated model where clinical laboratory operations serve as a self-funded R&D unit to validate products using real-world patient samples.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 30% to $24.0 million, driven primarily by a 34% increase in service revenue ($21.3 million) due to a 30% increase in case volume (15,470 cases vs. 11,894 cases). Product revenue grew slightly by 5% to $2.7 million.
• Profitability Improvement: Operating loss narrowed significantly from $4.2 million to $1.2 million. Net loss decreased from $4.3 million to $0.4 million.
• Liquidity Position: Working capital improved from a deficit of $0.8 million to a positive $2.3 million. Cash balances increased by $1.3 million, aided by $1.3 million in proceeds from warrant exercises and $0.8 million in Employee Retention Credit (ERC) refunds.
• Unusual Items: Net income included $0.8 million in ERC refunds and a $0.1 million gain on liability settlement. Conversely, the company recorded a $0.1 million write-off related to Change Healthcare temporary funding assistance.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The independent auditors have issued a "Going Concern" opinion. There is substantial doubt about the company's ability to continue as a going concern for the next twelve months due to an accumulated deficit of $102.8 million and a history of operating losses. Continued operations depend on raising additional financing and achieving business plan targets.
• Outlook: Management expects to incur net losses through at least the first half of 2026. Future liquidity depends on sustaining operating performance and accessing capital markets.
• Regulatory Risks:
  • FDA/LDTs: While a 2024 FDA rule on Laboratory Developed Tests (LDTs) was vacated in 2025, regulatory uncertainty remains. Future enforcement could require costly premarket approvals.
  • EU/UK Compliance: The company must meet strict EU IVDR transitional deadlines (application by May 2026, agreement by September 2026) to maintain market access for HemeScreen products in Europe and Northern Ireland.
• Cybersecurity: The company disclosed a cybersecurity incident in January 2026 involving unauthorized access to an employee's cloud storage, potentially exposing PII and PHI. An investigation is ongoing.
• Customer Concentration: One customer represented 26% of total revenue in 2025. Three customers accounted for 56% of total accounts receivable.

Investor Verification Checklist

• Capital Adequacy: Verify the company's ability to secure additional financing given the "Going Concern" warning and $2.7 million cash balance against significant operating expenses.
• Revenue Quality: Assess the sustainability of the 30% case volume increase and the concentration risk associated with the top customer (26% of revenue).
• Regulatory Milestones: Monitor the company's progress in meeting EU IVDR notified body deadlines in 2026 to avoid loss of European market access.
• Cybersecurity Impact: Track the resolution of the January 2026 data breach and any associated regulatory fines or litigation costs.
• Non-Recurring Income: Note that the 2025 net loss was significantly mitigated by one-time items ($0.8M ERC, $0.1M liability gain); evaluate core operating performance excluding these items.